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Objective. Mevalonate kinase deficiency (MKD)
is a rare metabolic disease characterized by recurrent
inflammatory episodes. This study was undertaken to
describe the genotype, phenotype, and response to treat-
ment in an international cohort of MKD patients.
Methods. All MKD cases were extracted from the
Eurofever registry (Executive Agency for Health and
Consumers project no. 2007332), an international, mul-
ticenter registry that retrospectively collects data on
children and adults with autoinflammatory diseases.
Results. The study included 114 MKD patients.
The median age at onset was 0.5 years. Patients had on
average 12 episodes per year. Most patients had gastroin-
testinal symptoms (n5 112), mucocutaneous involvement
(n5 99), lymphadenopathy (n5 102), or musculoskeletal
symptoms (n5 89). Neurologic symptoms included head-
ache (n5 43), cerebellar syndrome (n5 2), and mental
retardation (n5 4). AA amyloidosis was noted in 5
patients, almost twice as many as expected from findings
in previous cohorts. Macrophage activation syndrome
occurred in 1 patient. Patients were generally well between
attacks, but 10–20% of the patients had constitutional
symptoms, such as fatigue, between fever episodes.
Patients with p.V377I/p.I268T compound heterozygosity
had AA amyloidosis significantly more often. Patients
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without a p.V377I mutation more often had severe muscu-
loskeletal involvement. Treatment with nonsteroidal anti-
inflammatory drugs relieved symptoms. Steroids given
during attacks, anakinra, and etanercept appeared to
improve symptoms and could induce complete remission
in patients with MKD.
Conclusion. We describe the clinical and genetic
characteristics of 114 MKD patients, which is the larg-
est cohort studied so far. The clinical manifestations
confirm earlier reports. However, the prevalence of AA
amyloidosis is far higher than expected.
Mevalonate kinase deficiency (MKD) is a rare auto-
inflammatory syndrome characterized by fever and general-
ized inflammation. The disease encompasses a continuum
of 2 phenotypes, known as hyperimmunoglobulinemia D
with periodic fever syndrome (HIDS; MIM no. #260920)
and mevalonic aciduria (MA; MIM no. #610377) (1–4).
Patients with MKD present with fever, gastrointestinal (GI)
symptoms, lymphadenopathy, arthralgia, myalgia, skin rash,
and mucosal ulcers. Furthermore, patients with the more
severe phenotype mevalonic aciduria can also exhibit dys-
morphic features, prenatal and postnatal growth retarda-
tion, and neurologic and ocular involvement (5).
Both phenotypes are caused by mutations in the
MVK gene (6,7). This gene encodes mevalonate kinase,
an enzyme that is part of the mevalonate pathway. This
pathway produces cholesterol and unsaturated lipid
chains, known as nonsterol isoprenoids (8). Mevalonate
kinase activity is reduced in MKD patients, varying from
1.8% to 28% of the activity seen in healthy controls in
patients with the HIDS phenotype, to below 0.5% in
patients affected by the MA phenotype, although over-
lap occurs (6,9,10). The substrate of this enzyme,
mevalonic acid, accumulates and is excreted in the
urine. Patients with MKD therefore often excrete ele-
vated amounts of mevalonic acid (10–14). Due to the
lack of clinical criteria, patients can only be diagnosed
by the identification of 2 pathogenic MVK mutations or
by detection of decreased enzyme activity (15).
The first MKD patients were described in 1984
(2). Several hundred patients with this rare disease have
been identified to date. MKD has been more frequently
reported in patients with Caucasian ethnicity; a dispro-
portionate number of Dutch HIDS patients have been
described, probably due to the presence of a founder
mutation (p.V377I) in this population (16). The current
number of MKD patients is certainly an underestimate,
as many patients remain undiagnosed (8). Since many
physicians are still not familiar with this disease, the
mean diagnostic delay is 7.1 years (17). MKD patients
are often believed to have other diseases, such as
infections, immunodeficiency, or other autoinflammatory
syndromes, before being diagnosed correctly (17).
This study aimed to describe the clinical and
genetic characteristics and the response to treatment in
a large, international cohort in order to increase knowl-
edge about this rare disease and hence facilitate diagno-
sis and inform discussion of treatment and prognosis
with affected families.
PATIENTS AND METHODS
Patients. All patients were enrolled in the Eurofever
registry (Executive Agency for Health and Consumers project no.
2007332), an international, multicenter registry that retrospec-
tively collects information on patients with autoinflammatory dis-
eases. Patients were enrolled beginning in November 2009 (18).
Epidemiologic, demographic, and clinical data were collected by
local physicians and anonymized. Independent ethics committee
approval for enrolling patients was granted in accordance with
local requirements. Written informed consent was obtained from
patients (or from legal guardians in the case of patients who were
minors) according to local ethics regulations. Two experts on
MKD (AS and JF) checked the enrolled patient data for genetic,
biochemical, and clinical characteristics. For this analysis, all
cases enrolled until November 2014 were included. Patients har-
boring 2MVKmutations or harboring 1 mutation in combination
with an abnormal metabolic study result were considered to be
true MKD patients. The metabolic criteria used were either
increased urinary mevalonic acid or reduced mevalonate kinase
enzyme activity in leukocytes or fibroblasts.
Response to different treatments (taken either intermit-
tently based on current symptoms or on a regular basis) was clas-
sified as follows: complete response (complete control of the
clinical manifestations and normalization of laboratory parame-
ters), partial response (persistence of some clinical manifestations
161 paents
142 paents
11- no MVK analysis performed
7- no MVK mutaons found
1- incomplete clinical data
28 paents with 1 mutaon
excluded as metabolic studies did
not conﬁrm MKD
114 paents
Figure 1. Flow chart of the inclusion of patients with mevalonate
kinase deficiency (MKD) in the study.
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and/or abnormal laboratory findings), or failure (absence of any
substantial impact on disease activity or worsening).
Statistical analysis. All analyses were performed
using SPSS 21. Categorical variables are presented as frequen-
cies and percentages. Numeric variables are presented as the
median and interquartile range (IQR). To determine a geno-
type–phenotype relationship, differences in clinical features
between groups with specific genotypes were analyzed using
Fisher’s exact test. P values less than 0.05 were considered
significant.
RESULTS
Demographic data. Up to November 2014, 161
patients had been enrolled by their local physicians in
the Eurofever registry with a diagnosis of MKD. Nine-
teen of these patients were excluded because genetic test-
ing had not been performed, no MVK mutations were
found, or clinical data were incomplete. Another 28
patients with only 1 mutation were excluded since MKD
could not be confirmed by demonstration of decreased
mevalonate kinase activity or elevated urinary mevalonic
acid excretion (Figure 1).
A total of 114 patients (53 male and 61 female)
were enrolled from 31 centers in 12 countries. The major-
ity of these patients were born in Italy (n5 31) and The
Netherlands (n5 28) (Figure 2A). The median age at dis-
ease onset was 6 months (IQR 9 weeks to 19 months)
(Figure 2B). The median age at diagnosis was 6.5 years
(IQR 3.5–14.7 years). Thus, the median diagnostic delay
was 6 years (IQR 1.9–14.2 years) (Figure 2C). The median
follow-up period since age at onset was 11.5 years.
Genetic characteristics. Complete gene screen-
ing was performed in 47 (41%) of the patients, whereas
in 46 (40%) of the patients only the most relevant exons
Figure 2. Characteristics of the 114 patients with mevalonate kinase deficiency (MKD). A, Country of birth of the MKD patients. Other coun-
tries included Albania, Australia, Cyprus, Czech Republic, Morocco, Russia, and Turkey. B, Age at onset of MKD. C, Diagnostic delay
according to year of birth for patients born since 1980. D, Genotypes of all patients. In A, B, and D, the values in parentheses are the number of
patients.
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Figure 3. Features of inflammatory attacks in 108 patients with mevalonate kinase deficiency (MKD). A, Episode duration in days. B, Number
of episodes per year. C, Episode triggers in 51 of the MKD patients. Other triggers included cold (n5 4), exercise (n5 5), trauma (n5 2), food
(n5 1), menstruation (n5 4), fatigue (n5 6), and travel (n5 1).
Table 1. Clinical characteristics of the 114 patients with mevalonate kinase deficiency
No. of patients/
no. assessed (%)
Patients with
symptom present
during every
fever episode, %
Patients with
symptom present
during and
between fever
episodes, %
Disease pattern
Recurrent 99/114 (87) – –
Continuous with exacerbations 9/114 (8) – –
Continuous 6/114 (5) – –
Constitutional symptoms* 79/111 (71)
Malaise 70/108 (65) 53 23
Fatigue 69/109 (63) 52 35
Weight loss 16/102 (16) – –
Lymphoid organs 102/113 (90)
Generalized enlargement 39/103 (38) 36 22
Cervical lymphadenopathy 96/113 (85) 64 15
Painful lymph nodes 59/99 (60) 42 12
Mucocutaneous involvement 99/113 (87)
Aphthous stomatitis 67/111 (60) 37 15
Maculopapular rash 43/111 (39) 21 8
Urticarial rash 16/109 (15) 38 38
Exudative pharyngitis 31/109 (28) 16 10
Musculoskeletal involvement 89/113 (79)
Arthralgia 80/113 (71) 34 15
Myalgia 64/112 (57) 34 18
Arthritis 31/109 (28) 24 9
Severe musculoskeletal involvement† 8/110 (7)
Gastrointestinal symptoms 112/114 (98)
Abdominal pain 98/111 (88) 44 16
Diarrhea 93/111 (84) 38 11
Vomiting 76/110 (69) 29 18
Severe gastrointestinal involvement‡ 18/114 (16)
Ocular involvement 17/113 (15) – –
Conjunctivitis 11/113 (10) 9 36
Uveitis 2/113 (2) – –
Impaired vision 2/113 (2) – –
Cataract 3/113 (3) – –
Neurologic involvement 46/114 (41)
Headache 43/114 (38) 40 33
Mood disorders 23/95 (24) 43 25
Severe neurologic involvement§ 6/114 (5)
* Constitutional symptoms were defined as fever, malaise, fatigue, mood disorders, or weight loss.
† Severe musculoskeletal involvement was defined as flexion contractures, bone deformity, bone ero-
sion, persistent arthritis, osteitis, or osteolytic lesion.
‡ Severe gastrointestinal involvement was defined as aseptic peritonitis, gastrointestinal bleeding, intes-
tinal occlusion, gut perforation, abdominal adhesions, gastrointestinal ulcers, or perianal ulcers.
§ Severe neurologic involvement was defined as cerebellar syndrome, mental retardation, or aseptic
meningitis.
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were sequenced. In 4 (4%) of the patients only the most
relevant point mutations were screened. Ninety-six
(84%) of the patients harbored at least 1 p.V377I muta-
tion, 14 (12%) of which were homozygous. The second
most frequent mutation was p.I268T, occurring in 29
(25%) of the patients. None of them were p.I268T
homozygous (Figure 2D).
Two mutations were not present in the Infevers
database (19). A p.C152Y mutation was found in 1 patient.
This patient also had a p.V377I mutation and had a mild
clinical pattern, with no reported musculoskeletal or neuro-
logic manifestations. Since this mutation was not known to
be pathogenic, enzyme activity in both fibroblasts and leu-
kocytes was assessed, and both assays showed decreased
activity. Further, a 447_448insGCCTAC mutation, which is
not known to be pathogenic, was found in 1 patient who
also had a p.V377I mutation. This patient was not severely
affected, and had mostly GI symptoms, myalgia, and lymph-
adenopathy. Metabolic studies were not performed.
Clinical characteristics. Ninety-nine of the 114
patients had recurrent disease episodes, i.e., they recov-
ered completely between attacks. Six patients had contin-
uous disease without clearcut exacerbations, whereas 9
patients had a continuous course with exacerbations. In
these patients the intervals between attacks were charac-
terized by some measure of ongoing inflammation. The
median flare duration was 4 days, and the median flare
frequency was 12 episodes per year (Figures 3A and B).
Fever episodes were provoked by specific triggers in 51
patients, mainly by vaccination (n5 38), stress (n5 26),
and infection (n5 18) (Figure 3C).
MKD symptoms and sequelae. General features.
All clinical features are summarized in Table 1. Detailed
descriptions of patients with severe manifestations can
be found in Table 2. Seventy-nine patients had constitu-
tional symptoms, such as malaise (n5 70), fatigue
(n5 69), and weight loss (n5 16). In 23% of these
patients, malaise was reported independent of fever,
while fatigue occurred independent of fever in 35% of
them. Constitutional symptoms independent of fever
were not predictors of a more severe course such as
amyloidosis. Most patients (n5 102) had lymphadenop-
athy, which was usually, but not exclusively, cervical
(n5 96) and tender (n5 59). Generalized lymphade-
nopathy occurred in a sizeable minority (n5 39).
Mucocutaneous involvement. Ninety-nine patients
had mucocutaneous symptoms, such as aphthous stoma-
titis (n5 67) and pharyngitis (n5 31). Fifteen percent
of the patients had aphthous stomatitis independent of
fever. Maculopapular rash (n5 43) and urticarial-like
rash (n5 16) were seen between fever episodes in 8%
and 38% of the patients, respectively.
Musculoskeletal involvement. Musculoskeletal
symptoms were noted in 89 patients. Most had arthral-
gia (n5 80) or myalgia (n5 64), specifically during fever
episodes (in 85% and 82% of the patients, respectively).
Arthritis was less common (n5 31) and resolved when
the fever episode subsided in 91%. In total, 8 patients
had severe musculoskeletal involvement: flexion contrac-
tures (n5 5), persistent arthritis (n5 2), bone erosion
(n5 2), osteolytic lesions (n5 2), osteitis (n5 2), and
bone deformity (n5 1). These patients are described in
more detail below and in Table 2.
One patient (patient 1) with persistent poly-
arthritis developed contractures and bone deformity.
This patient also had severe GI symptoms, such as GI
bleeding and GI and perianal ulcers. The other patient
with persistent arthritis did not have other severe
manifestations.
Two brothers, who had a compound heterozy-
gous p.H20N and p.R215Q mutation, had flexion
contractures, bone erosion, and osteolytic lesions. The
older brother (patient 2) had involvement of 2 joints
and also had severe GI involvement, including aseptic
peritonitis, gut perforation, intestinal occlusion, and
abdominal adhesions. In addition, he had scleritis. The
younger brother (patient 3), who had continuous dis-
ease based on clinical features and chronic elevation of
parameters of inflammation, had involvement of 13
joints. Joint contractures appeared at the age of 2 years.
Two patients had osteitis. One of them (patient 4)
had a continuous disease pattern and had bacterial osteo-
myelitis. This patient also experienced aseptic peritonitis,
intestinal occlusion, and abdominal adhesions. The other
patient (patient 5) had osteitis without other severe mani-
festations. The osteitis was located in the right calcaneus.
No bacterial growth was observed during blood culture.
One patient had flexion contractures only.
GI involvement. GI symptoms were seen in 112
of the patients. Most of them experienced abdominal
pain (n5 98), diarrhea (n5 93), and vomiting (n5 76).
In .80% of these patients, these symptoms were only
seen during fever episodes. Eighteen patients had
severe GI symptoms: aseptic peritonitis (n5 7), GI
bleeding (n5 7), perianal ulcers (n5 5), intestinal
occlusion (n5 3), gut perforation (n5 2), and GI
ulcers (n5 2).
Abdominal adhesions were reported in 4 patients,
although the modality of identification of this complica-
tion (imaging or after surgery) was not specified. Two
sisters (patients 6 and 7) both had GI bleeding. The older
sister also had uveitis and scleritis, while the younger sis-
ter had flexion contractures.
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Patient 8 had aseptic peritonitis and perianal
ulcers. Another patient (patient 9) had aseptic peritonitis
and abdominal adhesions. One patient (patient 10), who
had a continuous disease course, had aseptic peritonitis,
GI bleeding, gut perforations, and abdominal adhesions.
This patient also experienced aseptic meningitis. She
died due to acute respiratory distress syndrome before
the age of 1 year. Ten additional patients had 1 severe
GI manifestation, namely, GI bleeding (n5 3), perianal
ulcers (n5 3), aseptic peritonitis (n5 2), intestinal
occlusion (n5 1), or GI ulcers (n5 1), without other
severe organ involvement.
Neurologic involvement. Headache was the most
common neurologic symptom (n5 43) and was reported
independent of fever in 33% of the patients. Mood
disorders were reported in 23 patients. Moreover, 25%
of these patients had mood disorders between fever epi-
sodes, thus reflecting the psychological impact of the
disease, irrespective of its recurrent or continuous
course. Six patients had severe neurologic manifesta-
tions, namely, mental retardation (n5 4), cerebellar
syndrome (n5 2), and aseptic meningitis (n5 1). One
patient (patient 11), who had a recurrent disease course,
experienced both a cerebellar syndrome and mild
mental retardation. This patient also had retinitis
pigmentosa and has been described before in a case
report (20). Another patient (patient 12) who had cere-
bellar disease also had a recurrent disease course. He
was diagnosed as having type 1 Arnold-Chiari cerebellar
syndrome as an incidental finding upon magnetic reso-
nance imaging of the brain performed at the age of 2
years. Despite this malformation, he showed normal
psychomotor development. He had a twin who died in
utero. One patient (patient 13) with mental retardation
was heterozygous for p.I268T and p.P165L and had coli-
tis as part of the MKD. The 2 other patients with mental
retardation (patients 14 and 15) had no other severe
manifestations.
Macrophage activation syndrome (MAS). MAS
occurred in 1 patient (patient 16) who had a hetero-
zygous p.V377I and deletion in exon 8 mutation
(p.Arg226fs). This patient has been described previously
(21). At that time, the patient was receiving only flurbi-
profen at full dosage, and the disease was apparently
well controlled. The MAS presented initially as a typical
MKD episode with high fever, arthralgia, myalgia, and
oral aphthae, which led to hospitalization. Two days
after hospitalization, the patient was treated with several
antibiotics due to presumed sepsis. The clinical picture
worsened, with initial heart failure and lethargy. Inten-
sive care support with continuous ventilation was
required. Bone marrow aspiration revealed activated
macrophages and numerous hemophagocytic cells. The
patient was treated with high-dose methylprednisolone
(30 mg/kg/day) for 4 days. Thereafter, maintenance ste-
roid therapy (1 mg/kg/day) and cyclosporine (4 mg/kg/
day) were given.
AA amyloidosis. AA amyloidosis was diagnosed
in 5 patients. The median delay to the diagnosis of
MKD in these 5 patients was 23 years (range 15–41
years). The median disease duration before the diagno-
sis of amyloidosis was 23 years (range 8–37 years).
One of these 5 patients (patient 17) had a
p.V377I mutation in combination with a p.L234P muta-
tion. He presented with end-stage renal failure at the
age of 39 years and also had involvement of the liver
and spleen. A renal transplantation was performed 2
years after the diagnosis of amyloidosis, with good graft
function.
The other 4 patients (patients 18–21) were com-
pound heterozygous for the p.V377I mutation and the
p.I268T mutation. In 1 of these 4 patients (patient 18),
AA amyloidosis presented with end-stage renal failure
at the age of 27 years and was diagnosed by biopsy,
showing involvement of the kidneys and spleen. She had
persistent inflammation with continuously elevated
parameters of inflammation. She died at the age of 45
years due to complications after 18 years of dialysis.
Patient 19 presented with end-stage renal failure
at the age of 19 years. Serum amyloid P (SAP) compo-
nent scintigraphy showed involvement of the kidneys,
spleen, and liver. He received renal transplants from liv-
ing related donors twice. The first kidney was lost due to
recurrent amyloid deposition. The second transplanta-
tion led to good graft function. After the first renal
transplantation, the disease was not well controlled with
anakinra and subsequently etanercept. During a period
of 5 years, the patient did not receive any biologic agent.
Four months before the second transplantation, treat-
ment with tocilizumab was started, with complete
response. In his brother (patient 20), amyloidosis was
diagnosed at the age of 37 years, after presentation with
end-stage renal failure. SAP scintigraphy showed
involvement of the kidneys, spleen, and liver. He
received a renal transplant from a living related donor a
year after diagnosis, with good results.
The last patient (patient 21) was diagnosed as
having amyloidosis at the age of 8 years. Treatment with
colchicine was started due to suspected familial Medi-
terranean fever. At the age of 12 years she underwent
kidney transplantation. When she was 18 years old, she
was diagnosed as having MKD. She died at the age of
19 years.
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Laboratory findings. Abnormal IgD levels were
found in 55 of 76 patients assessed. Other Ig levels were
also measured. IgA levels were elevated in 48 of 90
patients, while IgG levels were elevated in 14 of 91
patients. IgM levels were within the normal range in 81
of the 91 patients tested.
Measurement of urinary mevalonic acid was per-
formed in 40 patients; 37 of them showed elevated
excretion. Thus, 3 patients excreted normal amounts of
mevalonic acid. All 3 of these patients had typical MKD
symptoms. The first patient was homozygous for
p.V377I and had confirmed impairment of mevalonate
kinase enzyme activity. Urine was collected during a
fever episode. This patient has been described before in
a diagnostic study (22). The second patient was com-
pound heterozygous for p.R388X and stop397R. In this
patient mevalonic acid was measured as part of whole
organic acid screening. It is unknown whether the
patient was well or febrile during urine sampling.
The last patient was compound heterozygous for
p.V377I and p.V310M and had a mild clinical pattern.
In this patient urine was not collected during a fever
episode.
Enzymatic studies in both leukocytes and fibro-
blasts were performed in 19 patients. Reduced mevalo-
nate kinase enzyme activity in fibroblasts was found in 7
of 8 patients tested, while 15 of 16 patients tested
showed reduced enzyme activity in leukocytes. Unex-
pectedly, 1 patient with a homozygous p.V377I muta-
tion, typical MKD symptoms, and elevated urinary
mevalonic acid excretion exhibited normal enzyme activ-
ity in both fibroblasts and leukocytes.
Associations between genotype and pheno-
type. To analyze genotype–phenotype associations, we
divided all patients into 4 groups: patients who were
homozygous for p.V377I; patients who were compound
heterozygous for p.V377I and p.I268T; patients with 1
p.V377I mutation and a second mutation other than
p.V377I or p.I268T; and patients without a p.V377I muta-
tion. The frequency of MKD features was compared
between the groups. Four of the 25 patients with p.V377I/
p.I268T combined heterozygosity experienced amyloidosis,
as compared to 1 of 89 patients with other genotypes
(P5 0.049). Further, patients with mutations other than a
p.V377I mutation more often had a continuous disease
course, musculoskeletal involvement, severe musculoskele-
tal involvement, and severe GI involvement (Table 3).
Treatment. Nonsteroidal antiinflammatory drugs
(NSAIDs). NSAIDs were administered to 66 patients,
usually to treat the symptoms of attacks, and were benefi-
cial in 48 of them. Seven of these patients exhibited a
complete response to NSAIDs. Five of them took
NSAIDs during attacks only and not as maintenance
therapy. Two of them received NSAIDs as monotherapy,
and the other 5 received NSAIDs in combination with
corticosteroids. The response to steroids was reported as
complete in 4 of the patients and as partial in 1 patient.
Corticosteroids. Corticosteroids were given to 49
patients to treat fever attacks. Complete suppression of
inflammatory episodes was reported for 19 of them (16
Table 3. Associations between genotype and clinical characteristics of the patients with MKD*
Phenotype
Patients
with
p.V377I
and p.V377I
(n5 14)
Patients
with
p.V377I
and p.I268T
(n5 25)
Patients
with p.V377I
and other
mutation
(n5 57)
Patients
without
p.V377I
(n5 18) P
Continuous course 0 4 0 28 0.000†
Family history 45 38 29 53 NS
Constitutional symptoms 85 68 85 89 NS
Mucocutaneous involvement 100 76 91 78 NS
Gastrointestinal involvement 100 96 100 94 NS
Severe gastrointestinal involvement 0 16 12 39 0.02†
Lymphoid involvement 93 92 89 89 NS
Ocular involvement 21 8 11 35 NS
Neurologic involvement 64 48 30 47 NS
Severe neurologic involvement 14 4 2 20 NS
Musculoskeletal involvement 86 64 77 100 0.025†
Severe musculoskeletal involvement 0 0 4 33 0.001†
Amyloidosis 0 16 2 0 0.049‡
* Values are the percent of patients. MKD5mevalonate kinase deficiency; NS5 not significant.
† Patients without p.V377I versus all other groups, by Fisher’s exact test.
‡ Patients with p.V377I and p.I268T versus all other groups, by Fisher’s exact test.
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of the 19 had not received biologic agents), and some
improvement was reported for 21 patients. Five of 7 patients
who received maintenance corticosteroids experienced
some benefit; failure to respondwas noted in the other 2.
Colchicine and statins. Colchicine was received
by 21 patients; 13 of them did not respond to this treat-
ment, and only 1 patient, who was heterozygous for
p.V377I and p.S135L, had a complete response. Famil-
ial Mediterranean fever (MEFV) screening had not
been performed in this Caucasian patient from Italy.
The patient did not receive NSAIDs, steroids, or bio-
logic agents. Statins were used to treat 15 patients; in 11
patients this treatment failed. Moreover, 3 of them
experienced worsening of their disease. Four patients
noted some improvement of symptoms.
Biologic agents. Eight patients received anakinra
only during attacks, with 3 of them having a complete
response and the other 5 a partial response. Nineteen
patients received anakinra as maintenance therapy,
which led to complete remission in 3 of them and a par-
tial response in 13. In 3 patients anakinra was not effec-
tive. All 3 had a recurrent disease pattern. One of them
was severely affected and had cerebellar syndrome, men-
tal retardation, and retinitis pigmentosa. The 2 other
patients were mildly affected and did not have severe
manifestations. In at least 7 patients with an initial failure
to respond or partial response to anakinra, the dose of
anakinra was increased. This increase in dose did not
lead to complete remission. Four of these 7 patients have
switched to another therapy, and 3 of them are still
receiving anakinra. In another 6 patients with an initial
partial response to anakinra, the dose was not increased.
Three of them are still receiving anakinra.
Five patients were treated with canakinumab;
complete remission was achieved in 4 of them, and 1
had a partial response. The patient with a partial
response was p.V377I/p.G338D compound heterozy-
gous with disease that had failed to respond to NSAIDs,
steroids, anakinra, etanercept, and adalimumab before
the initiation of canakinumab. Two patients with a com-
plete response had had a partial response to anakinra
before treatment with canakinumab.
Etanercept was prescribed to 27 patients. It had
a beneficial effect in 16 patients, of whom 2 had a com-
plete response. Disease failed to respond to etanercept
in 11 patients.
DISCUSSION
This report presents the phenotypic and geno-
typic characteristics and the response to treatment in
the largest cohort of MKD patients described so far.
Moreover, the vast majority (87 of these patients) have
not been described in previous cohorts (10,23). This
large cohort enables us to provide a broad description
of the clinical features and treatment of this rare
disease.
In many respects, our study confirms the clinical
characteristics described in previous reports. Typically,
the disease starts within the first year of life. Onset after
the age of 4 years makes the diagnosis extremely
unlikely. The most common symptoms were fever,
abdominal pain, diarrhea, vomiting, lymphadenopathy,
arthralgia, myalgia, and aphthous stomatitis. Five
patients had AA amyloidosis, a frequency almost twice
that reported in previous cohorts (23). This might be
due to reporting bias, since these patients are more
likely to be enrolled in the registry. Still, this number
might be an underrepresentation due to the limited
follow-up period. The median age of enrolled patients
was only 12 years, while amyloidosis occurred after 18
years in 4 of the 5 patients. Only 1 patient in our cohort
experienced MAS, which is fewer than in the study by
Bader-Meunier et al (10).
Many patients had symptoms between attacks.
These included mainly constitutional symptoms, such as
fatigue, malaise, and headache, but also oral aphthous
ulcers. It has to be noted that these symptoms are also
very common in the general population and have been
seen at increased frequencies in patients with rheumatic
diseases (24,25). In our cohort, patients with constitu-
tional symptoms between attacks did not have a more
severe course such as amyloidosis.
According to the enrolling centers, up to 25% of
the patients displayed some mood disorders. In the orig-
inal survey, the definition of mood disorders was left to
the discretion of the enrolling physicians. However, this
relatively high frequency possibly reflects the psycholog-
ical impact of the disease, as previously reported by van
der Hilst et al (23).
Although uncommon, some patients in our series
did have severe musculoskeletal manifestations, such as
persistent arthritis. In these severe cases, the differentia-
tion between MKD and other pediatric rheumatic dis-
eases such as systemic juvenile idiopathic arthritis (JIA)
can be difficult. However, the disease course with fre-
quent, short attacks of fever alternating with prolonged
episodes of spontaneous remission renders diagnoses
like systemic JIA highly unlikely.
This study confirms previous findings that mea-
surement of IgD is not a reliable method to diagnose
MKD (15), since 28% of the patients tested in this
cohort did not have elevated IgD levels. Further, mea-
surement of urinary mevalonic acid is a sensitive method
PHENOTYPE AND GENOTYPE OF MKD 2803
of MKD screening, as 93% of the patients tested
excreted elevated amounts of mevalonic acid (10,22).
The failure to detect mevalonic acid in some patient
samples may be due to methodologic limitations, since
isotope dilution was not used in all of these patient sam-
ples. Unexpectedly, in 1 patient, mevalonate kinase
enzyme activity was reportedly entirely normal in the
presence of known pathogenic mutations and elevated
urinary excretion of mevalonic acid. Enzymatic studies
have been regarded as the diagnostic gold standard for
MKD (8). However, apparently even enzyme activity
assays may yield false-negative results.
The most frequent combination of mutations was
p.V377I/I268T heterozygosity, occurring in 22% of the
patients, followed by p.V377I homozygosity in 12%.
Patients with a combined heterozygosity for p.V377I/
p.I268T had AA amyloidosis significantly more often.
As reported previously (23,26), treatment with
statins and colchicine was not effective in most patients.
Seventy-five percent of the patients experienced at least
some benefit when using NSAIDs, but efficacy was
rarely complete. Corticosteroids are more effective for
terminating inflammatory attacks, but long-term side
effects are a major drawback. Interleukin-1 (IL-1)
blockade is beneficial in many MKD patients, but appar-
ently not as effective as observed in the IL-1–driven
cryopyrin-associated periodic syndromes (26). Although
the number of MKD patients in the present study is sub-
stantially higher than that in a previous study on therapy
in the Eurofever cohort (26), the findings regarding
therapy remain essentially unchanged. Some patients
did not benefit from the use of biologic agents. From
the available data, the possibility that these patients
received an insufficient dose cannot be excluded. How-
ever, in 7 patients, an increase in the anakinra dose did
not result in the complete control of symptoms.
The retrospective design of the Eurofever regis-
try comes with a number of limitations. Due to this
design, there were a number of variables reported as
“not known” by the centers. This was mainly due to the
fact that some variables requested by the Eurofever reg-
istry could not be retrieved from the clinical chart,
because they were not investigated at the time of the
patients’ evaluation. This issue might have introduced a
bias, with a possible underrepresentation of some symp-
toms. For that reason, we have chosen to use the num-
ber of known values as the denominator in the tables.
Further, the Eurofever Registry collects data on
patients with periodic fever. The participating physicians
are pediatric immunologists and pediatric rheumatolo-
gists. Since patients with mevalonic aciduria experience
predominantly neurologic symptoms, these patients are
more likely to be seen by a pediatric neurologist or a
specialist in metabolic diseases. Therefore, some of the
more severely affected MKD patients may not have
been enrolled. In addition, patients with mevalonic acid-
uria may be underrepresented since they are more likely
to die at a young age (12). Still, our cohort included
some patients who could be classified as having
mevalonic aciduria. Also, many patients were enrolled
by European centers since the Eurofever registry is pre-
dominantly known in Europe.
Finally, the involvement of more pediatric than
adult specialists may have introduced an age bias. MKD
does not seem to carry a high mortality rate, yet the
median age of enrollment in our cohort was 12 years. A
long follow-up period is needed to acquire information
about long-term complications. A limitation to the inter-
pretation of therapeutic interventions is the absence of
clear criteria for complete and partial response. The
response was left to the interpretation of the physician.
Bias is inevitable due to the lack of control groups and
randomization. Furthermore, since it is unknown
whether drugs were used simultaneously or sequentially,
it is even more difficult to draw solid conclusions about
the efficacy of treatments. However, the Eurofever reg-
istry does provide information on current practice.
In conclusion, we have described the clinical and
genetic features in the largest international cohort of
MKD patients to date. Most MKD patients experienced
fever, accompanied by GI symptoms, lymphadenopathy,
arthralgia, and aphthous stomatitis. AA amyloidosis
(occurring in 4% of the patients) and MAS (occurring
in 0.9% of the patients) were rare, but severe, com-
plications of MKD. Some patients benefited from treat-
ment with NSAIDs, steroids, or biologic agents, mainly
IL-1 blockers and etanercept. Statins and colchicine
were usually not effective in treating MKD.
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